BSECompany Update22 Aug 2026 · 22 Aug 2026, 04:25 pm

Receipt of In Principle Approval

Parmax Pharma Ltd · 540359

✦ AI Summary▲ PositiveFundraise

Parmax Pharma Ltd has received in-principle approval from BSE Limited under Regulation 28(1) of the SEBI LODR Regulations for the issuance of equity shares and warrants on a preferential basis.

Analysis Scores

Earnings Impact6/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk5/10
Balance Sheet Risk2/10
Liquidity Impact9/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Parmax Pharma Ltd - 540359 - Receipt Of ''In-Principle'' Approval Under Regulation 28(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Issuance Of Equity Shares And Warrants On Preferential Basis

Attachments (1)

📄

c2e3ffc2-4d93-4f17-94f9-7aa9f929b834.pdf

pdf

Download →
View document text
parmaX Mfg. of : Bulk Drugs, Drug Intermediates & Speciality Chemicals PHARMA LTD. Date: August 22, 2026 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai — 400 001 Scrip Code: 540359/PARMAX SUBJECT: INTIMATION REGARDING RECEIPT OF'I N- PRINCIPLE’ APPURNDEOR RRVEEGGUUALLAATTLIIOONN 28(1) OF THE SEBI (LISTING OBLIGATIONSS AND DDIISSCCLLOO:S URE REQUIREMENTS) RREEGGUULLAATTIIOONNSS,, 22001155 FOR ISSUANCE OF EQUITY SHARES AND WAARRRRAANNTTSS ON PREFERENTIAL BASIS Dear Sir/Madam, Further to our intimation dated 8 June 2026, we wish to inform you that BSE Limited (‘Exchange'/'BSE'), vide its letter no. LOD/PREF/DA/FIP/693/2026-27 dated August 21, 2026, has granted its 'In-Principle' Approval under Regulation 28(1) of the SEBI LODR Regulations for the proposed issuance of the following securities on a preferential basis to the allottes as per Notice of the EGM: @ 31,37,586 (Thirty One Lakh Thirty Seven Thousand Five Hundred and Eighty Six) Equity Shares of face value of Rs. 10/- each at a price of not less than Rs.36.50/- (Rupees Thirty Six and Fifty Paise only) per share; and @ 21,45,145 (Twenty One Lakh Forty Five Thousand One Hundred and Forty Five) Warrants convertible into an equal number of Equity Shares of face value of Rs. 10/- each at a price of not less than Rs.36.50/- (Rupees Thirty Six and Fifty Paise only) per warrant. The In-Principle approval is subject to necessary compliance under Applicable SEB! regulations. This is for your information and records. Kindly take the same on record. Thanking you, Yours faithfully, Yiorabs. For Parmax Pharma Limited Umang Gosalia DIN: 05153830 Managing Director PARMAX PHARMA LIMITED Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504 Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)